GLP–1s for Pediatric Obesity: Worth a Shot?

By Marcus A. BanksAlthough several glucagon-like peptide-1 receptor agonists (GLP-1s) are approved for adolescents, their use raises concerns about insurance disparities and starting long-term therapy in childhood. At the ASHP Midyear 2025 Clinical Meeting & Exhibition, in Las Vegas, experts debated the merits of prescribing GLP-1s to pediatric patients with obesity in a session titled, “Is It Worth a Shot?”Kelly L. Matson, PharmD, BCPPS, a clinical professor at the University of